In confirmation and extension of observations by Carp and his associates, brain tissue and sera from patients with multiple sclerosis (MS) were found to harbor an agent which induces a transitory depression in polymorphonuclear leukocytes (PMN) in mice as well as in rats, hamsters, and guinea pigs. All of eight MS brains contained this agent at titers as high as 10-g/g of brain tissue. The agent was found in MS sera at titers up to 10-3/ml of serum, but its presence depended to some extent on the clinical status of the patients; it was observed more frequently in sera of patients with active disease (73%) than in sera of patients with quiescent disease (31%). Control brain tissues or sera failed to induce PMN depressions. The apparently MS-associated agent (MSAA) passed through 50-nm but not 25-nm membrane filters (Millipore Corp.) and was largely sedimented at 105,000 x g but not at 50,000 x g for 1 h. It multiplied to high titers in the central nervous tissue of the inoculated animals and could be serially transmitted from animal to animal by passage of brain homogenates. Various observations and considerations appear to preclude that MS-associated agent represents an indigenous animal virus. Although its role in MS remains to be determined, it should be considered a candidate for the etiology of this disease.
It has long been suspected that multiple sclerosis (MS) might be caused by a virus. Whereas several viruses have been implicated on a serological basis or by isolation from involved central nervous tissue, none have been proven to be etiologically related to the disease (cf. 4). Recently, Carp and his associates (2) reported that intraperitoneal or intracerebral injection of specimens from MS patients into inbred mice rapidly induced persistent changes in the differential counts of circulating leukocytes, i.e., a decrease in the percentage and absolute number of polymorphonuclear leukocytes (PMN). The factor causing the PMN depression was found in all MS specimens tested, i.e., three brains, one spleen, three sera, and two cerebrospinal fluids from a total of nine patients. It was not demonstrable in similar numbers of specimens of each type derived from patients with other diseases. The factor was present in MS brain homogenates at concentrations of up to 102 U/g of tissue, was passable through 50-nm but not 25-nm membrane filters (Millipore Corp.), clearly multiplied in the brain of the injected animals, and could be passed to other mice.
These observations indicated that the factor causing the PMN depression was a small virus with unusual biological activities, either derived from the MS specimens or activated by them in the injected mice. It was essential to confirm these findings, to exclude a latent murine virus, and to relate the agent to man, and in particular to MS. Since total and differential leukocyte counts in mice are notoriously variable and influenced by many factors (cf. 5) , the findings of Carp and his co-workers could not be confirmed in a small experimental series (1) . As will be shown below, the essential observations of Carp and his group could be reproduced, although with considerable difficulties. For convenience, the agent present in MS specimens will be referred to as MS-associated agent (MSAA). Inoculation of animals and preparation of blood smears. MS and control materials were injected usually intraperitoneally (0.2 ml), rarely intracerebrally (0.03 ml). Blood smears were prepared at varying times thereafter depending on the strain of mice, since some were found to respond faster than others. Bleeding of the mice from the heart, orbital sinuses, or axillary blood vessels yielded lower percentages of PMNs and also more variable results than bleeding from the severed tip of the tail, which was adopted as standard procedure. Only the first free-flowing drops of blood were used for smears. This procedure permitted repeated testing of mice, but the intervals had to exceed 2 weeks to avoid irregular results due to the healing process or possibly infections. Rats were bled in the same manner. Blood from guinea pigs and hamsters was obtained by cardiac puncture under light ether anesthesia.
The air-dried blood smears were fixed with methanol and stained with Giemsa solution by standard methods. The smears were coded by one person and read by others without knowledge of their identity to avoid bias. At least 100 leukocytes were counted and classified as granulocytes or mononuclear cells. In the initial experiments groups of three, later four, and up to eight mice received the same inoculum. The mean percentages of PMNs recorded in the experimental groups were compared with those of the controls, and the differences were expressed as percentage of reduction of the control values. The significance of these results was determined by calculation of the P values by the two-tailed test, with P c 0.05 taken as significant.
Passage of MSAA. At varying times after injection of MS or control materials, animals were sacrificed, the brains were removed aseptically and homogenized as described, and the suspensions, after appropriate dilution, were injected into new groups of mice. Blood smears were obtained at given intervals, and the animals were subsequently sacrificed for further passages in the same manner. Sufficient numbers of serial passages were carried out to assure that the estimated cumulative dilution factors far exceeded the titers of MSAA in the MS specimens used for initiation of the passage series.
Filtration procedures. Ten-or 100-fold-diluted mouse passage brain homogenates were clarified at 10,000 x g for 1 h and passed successively through 450-, 220-, 100-, 50-, and 25-nm membrane filters (Millipore Corp.). MS sera were filtered in the same manner after 5-or 25-fold dilution in PBS. Samples of the original materials and the various filtrates were then injected into mice, and blood smears were prepared and analyzed 1 to 2 weeks later as described.
High-speed centrifugation. Test specimens, prepared as for the filtration experiments, were subjected to 50,000 x g or 105,000 x g in a Spinco preparative centrifuge, and the starting materials, the supernatant, and the pellets, resuspended in PBS to the original volumes, were tested in mice by the usual procedure.
RESULTS

It has been emphasized in Materials and
Methods that for demonstration of PMN depressions after injection of MS specimens it is essential to have mice in a uniformly healthy state. This condition was not always met by the dealers, and some experiments failed on that account. Other reasons for experimental failures will become apparent later. Yet, satisfactory results were obtained in many tests.
Inoculation of MS brain homogenates. Table 2 presents in detail several experiments in which mice were injected intraperitoneally with MS and control brain homogenates. The percentages of PMNs observed in individual mice after injection of MS brain suspensions were usually all lower than the lowest value found in mice injected with control brain homogenates. The reductions in the mean percentages of PMNs, as compared to the controls, were as high as 66% and highly significant.
Several MS brain homogenates were titrated in serial 10-or 100-fold dilution steps and highly significant PMN depressions were induced with dilutions as high as 10-9. Figure 1 shows the results of two separate titrations with the means and the spread of PMN percentages. The figures for the two control brain homogenates used as a 10-1 dilution matched those obtained with dilutions of the MS brain suspensions beyond the end point of activity. As will be shown later, mouse passage brain suspensions may yield similarly high titers.
Inoculation of MS sera. Sera from healthy donors generally failed to cause significant 5 and 27 days after injection were all of statistical significance. In the passage series shown, the original MS brain homogenate and the MS serum had ultimately been diluted by a factor of at least 10-:I0 and 10-12.4, respectively, i.e., far beyond the titers of MSAA in the starting materials.
PMN depressions induced in species other than mice. In as yet limited efforts, it was noted ( Table 9 ) that PMN depressions may be induced not only in mice, but in rats, guinea pigs, and hamsters as well. An MS brain homogenate was injected into guinea pigs, MS sera were injected into rats, and mouse passage brain homogenates from animals that had responded positively to injection of an MS serum or MS brain were injected into rats and hamsters, respectively. The reductions in the mean percentages of PMNs as compared to the controls ranged from 40 to 78%. Passage of a brain homogenate from two groups of rats induced PMN depressions in mice.
Some properties of the PMN depressing agent. Table 10 shows that the agent in MS sera passes through 50-nm but not 25-nm membrane filters (Millipore Corp.) as described by Carp et al. (2) . Similar results were obtained with mouse passage brain homogenates. It was noted repeatedly that the 50-nm filtrates of MS sera may cause more severe depressions of PMNs than the specimens before or after passage through larger filters, as, for example, serum GE-75. Sera from healthy donors, e.g., serum J. H. in the table, gave negative results before as well as after filtration through 50-nm membrane filters. MS brain homogenates and MS sera were also subjected to high-speed centrifugation. There was no detectable sedimentation of the agent when centrifuged at 50,000 x g for 1 h. It was extensively or totally sedimented from MS brain suspensions by centrifugation at 105,000 x g (Table 11 ). When MS sera were subjected to 105,000 x g, the activity was usually divided between the supernatants and the resuspended pellets. Compared to earlier assays, two of the sera (GE-55 and GE-87) showed a decline in activity when tested in 1:25 or 1:5 dilutions, respectively. However, after centrifugation serum GE-55 caused significant PMN depressions. It is conceivable that the small quantities of MSAA present in sera do not (2) . MS brain homogenates and MS sera may contain an agent which, under appropriate conditions, induces a depression in the relative concentration of PMNs in mice and also, as shown here, in rats, guinea pigs, and hamsters. The reduction in PMNs, however, was not as persistent as reported, and normal percentages were found generally when the animals were retested 2 or more months after inoculation. The responsible agent passed through 50-nm but not 25-nm membrane filters and was largely sedimentable at 105,000 x g and not at 50,000 x g. It was found to be labile even at 4 C, rather than stable as previously described (2) . The agent clearly replicated in the brains of injected mice and was serially transmissible from animal to animal. It is presently unknown whether the PMN depressions are due to a direct action of MSAA on these cells or their precursors or due to a by-product of the interactions of the agent with other tissues, such as the central nervous system.
All of the eight MS brain homogenates tested induced PMN depressions, but none of 11 control brain suspension did. Although not all MS sera revealed the presence of the agent, these differential results appeared to be referable to some extent to the clinical status of the patients; that is, sera from patients with active disease induced PMN depressions more frequently then sera from patients with quiescent disease. None of eight spinal fluids from MS patients caused reductions in the percentages of PMNs. In fact, these spinal fluids, as well as some of the negative MS sera, were found to neutralize the agent, as will be reported in the accompanying paper (3) .
The agent appears to be a virus, since it replicates in the injected animals and can be serially transmitted. It seems unlikely that the agent represents an indigenous animal virus for the following reasons: (i) injection of control materials from patients with other neurological or nonneurological diseases failed to cause PMN depressions; (ii) passages ofbrain homogenates from mice, either uninjected or injected with control specimens, likewise gave negative results; (iii) the factor in MS specimens is retained by 25-nm but not 50-nm membrane filters, as is the agent in mouse passage brain homogenates; (iv) PMN depressions were induced in all strains of mice tested as well as in three other species of animals, and it would be surprising to find the same latent agent in all; and, finally, (v) as will be shown (3), certain human sera were found to neutralize the agent as present in MS specimens or mouse passage material. According to these observations and considerations, the agent appears to be associated with MS and therefore has been called MSAA, but its role in this disease remains to be determined. Whereas leukocyte counts in MS are within normal range, PMN depressions might occur well before diagnosis since they are seen early and are transient in animals.
The present assay for MSAA, the induction of PMN depression in mice, is unfortunately beset with all the inherent vagaries of leukocyte counts in experimental animals (cf. 5). Irregular results are often observed if the mice are not in a prime state of health, if the blood smears are not prepared at a uniform time of day, and if the animals become unduly agitated during handling. Furthermore, the evident lability of the agent during prolonged storage and on repeated freezing and thawing of specimens has been a cause of experimental failures. This has been especially apparent with MS sera, in which the concentration of MSAA is relatively low. It is probable, too, that with low-titered specimens only part of the animals will receive a dose of MSAA sufficient to cause PMN depressions (as in any virus titration at end point dilutions), and thus the mean PMN percentages may not reflect significant reductions when compared to the control values. In addition, some sera may have components which actually cause slight increases in the percentages of PMNs which could counteract the effects of MSAA. Finally, there is an indication that some MS sera may contain both MSAA and neutralizing antibodies, partly as complexes, (3), which may account for the occasionally greater PMN depressions observed with diluted MS sera or with 50-nm membrane filtrates than with more concentrated or unfiltered sera.
From the above remarks it is evident that the test procedure applied to sera from MS patients is beset with difficulties and thus cannot be considered a dependable tool. It is possible, and this deserves further exploration, that passages of brain homogenates from the initially inoculated mice might improve the reliability of the test. It would be far more desirable, however, to develop more convenient and dependable means for detection of MSAA and, in turn, for measuring neutralizing activity in human sera. Limited attempts to transmit the agent to cultures of various types of cells have failed to induce detectable cytopathic effects. However, several cell lines were established from brains of animals inoculated with MS specimens, but not from brains of control animals. The continuous cultures obtained were found to harbor MSAA, as will be reported later (P. Koldovsky, U. Koldovsky, G. Henle, and W. Henle, 
